Cost-Utility Analysis of Dapagliflozin Versus Saxagliptin Treatment as Monotherapy or Combination Therapy as Add-on to Metformin for Treating Type 2 Diabetes Mellitus

Applied Health Economics and Health Policy ◽

10.1007/s40258-020-00603-7 ◽

2020 ◽

Vol 19 (1) ◽

pp. 69-79 ◽

Author(s):

Shanshan Hu ◽

Xun Deng ◽

Yanjiao Ma ◽

Zhilei Li ◽

Yuhang Wang ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Combination Therapy ◽

Cost Utility ◽

Cost Utility Analysis ◽

Utility Analysis

Download Full-text

Cost-Utility Analysis of Intensive Blood Glucose Control with Metformin versus Usual Care in Overweight Type 2 Diabetes Mellitus Patients in Beijing, P.R. China

Value in Health ◽

10.1111/j.1524-4733.2008.00363.x ◽

2008 ◽

Vol 11 ◽

pp. S23-S32 ◽

Author(s):

Xuanqian Xie ◽

Hindrik Vondeling

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Blood Glucose ◽

Glucose Control ◽

Blood Glucose Control ◽

Cost Utility ◽

Cost Utility Analysis ◽

Utility Analysis

Download Full-text

Empagliflozin in Type 2 Diabetes Mellitus Patients with High Cardiovascular Risk: A Model-Based Cost-Utility Analysis in China

Diabetes Metabolic Syndrome and Obesity Targets and Therapy ◽

10.2147/dmso.s266901 ◽

2020 ◽

Vol Volume 13 ◽

pp. 2823-2831

Author(s):

Peng Men ◽

Tianbi Liu ◽

Suodi Zhai

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Cardiovascular Risk ◽

Cost Utility ◽

Cost Utility Analysis ◽

Utility Analysis ◽

High Cardiovascular Risk ◽

Download Full-text

PDB79 - COST-UTILITY ANALYSIS OF INSULIN GLARGINE 300 U/ML VERSUS INSULIN GLARGINE 100 U/ML AND INSULIN DEGLUDEC 100 U/ML IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN CROATIA

Value in Health ◽

10.1016/j.jval.2018.09.784 ◽

2018 ◽

Vol 21 ◽

pp. S131-S132

Author(s):

M. Bogdanovic ◽

M. Fournier ◽

D. Vitezic

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Insulin Glargine ◽

Cost Utility ◽

Cost Utility Analysis ◽

Insulin Degludec ◽

Utility Analysis

Download Full-text

Cost–utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in Type 2 diabetes mellitus

Diabetic Medicine ◽

10.1111/j.1464-5491.2011.03429.x ◽

2012 ◽

Vol 29 (3) ◽

pp. 313-320 ◽

Author(s):

M. J. Davies ◽

B. D. Chubb ◽

I. C. Smith ◽

W. J. Valentine

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Cost Utility ◽

Cost Utility Analysis ◽

Utility Analysis ◽

Metformin Monotherapy

Download Full-text

PDB35 COST-UTILITY ANALYSIS OF BIPHASIC INSULIN ASPART VERSUS HUMAN INSULIN IN TYPE 2 DIABETES MELLITUS PATIENTS TREATED IN TIER III HOSPITALS IN BEIJING, CHINA: A LONGTERM OUTCOMES MODEL EVALUATION FROM THE IMPROVE OBSERVATIONAL STUDY

Value in Health ◽

10.1016/s1098-3015(10)66683-1 ◽

2008 ◽

Vol 11 (6) ◽

pp. A507

Author(s):

J White ◽

M Aagren ◽

L Jing

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Observational Study ◽

Cost Utility ◽

Cost Utility Analysis ◽

Utility Analysis ◽

Biphasic Insulin ◽

Download Full-text

Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus

Clinical Cornerstone ◽

10.1016/s1098-3597(01)90030-4 ◽

2001 ◽

Vol 4 (2) ◽

pp. 65

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Diabetic Retinopathy ◽

Cost Utility ◽

Cost Utility Analysis ◽

Utility Analysis ◽

Screening Intervals

Download Full-text

Cost-Utility Analysis of Screening Intervals for Diabetic Retinopathy in Patients With Type 2 Diabetes Mellitus

JAMA ◽

10.1001/jama.283.7.889 ◽

2000 ◽

Vol 283 (7) ◽

pp. 889 ◽

Author(s):

Sandeep Vijan

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Diabetic Retinopathy ◽

Cost Utility ◽

Cost Utility Analysis ◽

Utility Analysis ◽

Screening Intervals

Download Full-text

PDB86 - COST-UTILITY ANALYSIS OF INSULIN GLARGINE 300 U/ML VERSUS INSULIN GLARGINE 100 U/ML AND INSULIN DEGLUDEC 100 U/ML IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN BULGARIA

Value in Health ◽

10.1016/j.jval.2018.09.791 ◽

2018 ◽

Vol 21 ◽

pp. S133

Author(s):

M. Bogdanovic ◽

J. Mihajlović ◽

M. Fournier

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Insulin Glargine ◽

Cost Utility ◽

Cost Utility Analysis ◽

Insulin Degludec ◽

Utility Analysis

Download Full-text

Cost-utility analysis of second-line anti-diabetic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin

Current Medical Research and Opinion ◽

10.1080/03007995.2020.1815686 ◽

2020 ◽

Vol 36 (10) ◽

pp. 1619-1626

Author(s):

Ching-Lun Chien ◽

Yen-Chou Chen ◽

Daniel C. Malone ◽

Yueh-Lung Peng ◽

Yu Ko

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Cost Utility ◽

Cost Utility Analysis ◽

Second Line ◽

Utility Analysis

Download Full-text

Abstract #1141: Efficacy and Safety of Initial Combination Therapy with Canagliflozin (CANA) and Metformin Extended-Release (Met) in Drug-Naïve Patients with Type 2 Diabetes Mellitus (T2DM) By Latino/Hispanic Ethnicity

Endocrine Practice ◽

10.1016/s1530-891x(20)44270-3 ◽

2017 ◽

Vol 23 ◽

pp. 312

Author(s):

Jaime Davidson ◽

Julio Rosenstock ◽

Ujjwala Vijapurkar ◽

Michael Davies ◽

Anita Conner ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Combination Therapy ◽

Extended Release ◽

Efficacy And Safety ◽

Initial Combination Therapy ◽

Drug Naïve ◽

Initial Combination

Download Full-text